📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-12 19:19
510 analysed today
510
Today
133,399
All-time analysed
40,108
Positive
6,279
Negative
79,197
Neutral
7,747
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
5 announcements match the current filters (relevance ≥ 5).
Kerala Ayurveda to Merge Profitable WOS Ayurvedagram; Subsidiary PAT at ₹3.16 Cr
Kerala Ayurveda's board has approved the amalgamation of its wholly-owned subsidiary (WOS), Ayurvedagram Heritage Wellness Centre, into the parent company. The subsidiary is notably profitable, reporting a PAT of ₹3.16 Cr on a turnover of ₹15.47 Cr for FY26, which will help offset the parent's standalone losses of ₹14.74 Cr. The merger involves no share issuance or cash consideration as it is a 100% subsidiary. Additionally, the company granted 64,875 ESOPs at an exercise price of ₹10 and re-appointed Mr. Ramesh Vangal as a Director.
Confidence: HIGH
What changedThe company is consolidating its corporate structure by merging its profitable wellness center subsidiary into the loss-making parent entity.
Why it mattersThis merger simplifies the corporate structure, reduces administrative overheads, and directly integrates a profit-making business unit into the parent's balance sheet, which currently faces high debt and negative earnings.
Subsidiary Turnover (FY26): ₹15.47 CrSubsidiary PAT (FY26): ₹3.16 CrParent Standalone Loss (FY26): ₹14.74 CrSubsidiary vs Parent Revenue Ratio: 18.1%ESOP Exercise Price: ₹10
📅 Short termThe news is likely to be viewed positively as it brings a profitable unit directly into the listed entity, though the process involves regulatory approvals.
📈 Long termStructural consolidation should improve operational efficiency and financial transparency, though the high debt-to-equity ratio of 7.82 remains a long-term challenge.
⚠ Risk flags
- High debt-to-equity ratio (7.82)
- Regulatory and NCLT approval risks for the merger
- Historical loss-making status of the parent entity
Key Highlights
Subsidiary turnover of ₹15.47 Cr represents approximately 18% of the parent's standalone FY26 revenue of ₹85.48 Cr
Subsidiary reported a PAT of ₹3.16 Cr for FY26, while the parent company recorded a standalone loss of ₹14.74 Cr
Subsidiary Net Worth stands at ₹16.23 Cr as of March 31, 2026, compared to the parent's ₹36.15 Cr
Grant of 64,875 ESOPs at an exercise price of ₹10 per share, significantly below the current market price of ₹155.8
The merger is subject to NCLT and shareholder approvals with no change in the shareholding pattern
👀 What to Watch
Investors should monitor the timeline for NCLT approval and the subsequent impact on standalone profitability and debt-servicing capability once the profitable subsidiary is absorbed.
16% Revenue Growth in Q1 FY27; Kerala Ayurveda Targets Rs 1,000 Cr Revenue by FY30
Kerala Ayurveda reported Q1 FY27 consolidated revenue of 33.2 Cr, a 16% YoY increase, while narrowing its operating EBITDA loss to 3.82 Cr from 7.10 Cr in the previous quarter. Despite topline growth, the company posted a net loss of 8.08 Cr, significantly impacted by a 5x surge in promoter loan interest costs. Management reaffirmed its 'Vision 2030' to scale revenue to 1,000 Cr and expects monthly operating EBITDA breakeven by September 2026. The company is also planning to convert promoter loans to equity to improve its high debt-to-equity ratio, which currently stands at 7.82.
Confidence: HIGH
What changedThe company is transitioning from a heavy loss-making phase toward operational breakeven, supported by high-growth digital segments and international expansion, while addressing its debt through equity conversion.
Why it mattersWith a low net worth of 11 Cr and high debt of 86 Cr, the company's survival and growth depend on reaching operational profitability to service interest costs and successfully executing its aggressive 10x revenue expansion plan.
Q1 FY27 Revenue: 33.2 CrYoY Revenue Growth: 16.0%Operating EBITDA Loss: -3.82 CrVision 2030 Revenue Target: 1,000 CrPromoter Loan Interest Increase: 5xTTM Revenue vs Vision 2030 Target: ~13.1%
📅 Short termThe reduction in operating losses is a positive signal, but the high interest burden remains a significant drag on the bottom line in the immediate weeks.
📈 Long termThe Vision 2030 target is highly aggressive, requiring a massive CAGR; success depends on scaling the US and E-commerce businesses and the successful execution of the JV resorts in India and Costa Rica.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High debt-to-equity ratio (7.82)
- Significant interest cost from promoter loans
- Geopolitical risks affecting international guest arrivals
- Historical vulnerability to natural disasters in Kerala
Key Highlights
Consolidated revenue grew 16% YoY to 33.2 Cr in Q1 FY27, led by a 28.3% growth in standalone operations.
Operating EBITDA (Adj.) loss reduced by ~50% sequentially to 3.82 Cr from 7.10 Cr in Q4 FY26.
India D2C e-commerce segment grew 38.9% YoY, with repeat customer contribution rising to 33%.
US Wellness Clinic revenue surged 81.9% YoY, offsetting an 8.2% decline in the US Academy segment.
Vision 2030 targets a 10x revenue increase from 100 Cr in FY24 to 1,000 Cr by FY30.
👀 What to Watch
Monitor the achievement of the September 2026 monthly EBITDA breakeven target and the execution of the promoter loan-to-equity conversion in H2 FY27. Investors should also track the launch of the Karwar resort in October 2026 and the new premium brand in November 2026 as key growth drivers.
Kerala Ayurveda to Merge Profitable Rs 15.47 Cr WOS; Grants 64,875 ESOPs
Kerala Ayurveda's board has approved the merger of its wholly-owned subsidiary, Ayurvedagram Heritage Wellness Centre, into the parent company to streamline operations and eliminate duplicative costs. The subsidiary is profitable, reporting a PAT of Rs 3.16 Cr on a turnover of Rs 15.47 Cr for FY26, which will support the parent company that reported a loss of Rs 14.74 Cr in the same period. Additionally, the company granted 64,875 ESOPs at an exercise price of Rs 10 per share and recommended the re-appointment of Mr. Ramesh Vangal as a Non-Executive Director.
Confidence: HIGH
What changedThe company is moving from a multi-entity structure to a consolidated one by merging its profitable wellness resort subsidiary into the parent, while also issuing new equity incentives to employees.
Why it mattersThe merger is financially significant as it brings a profit-making unit directly into the parent's books, potentially improving the standalone balance sheet which currently shows high debt (Rs 86 Cr) and low net worth (Rs 11 Cr per TTM data).
Subsidiary FY26 Turnover: Rs 15.47 CrSubsidiary FY26 PAT: Rs 3.16 CrParent FY26 Loss: Rs 14.74 CrESOP Exercise Price: Rs 10.00Subsidiary vs TTM Revenue: ~11.8%
📅 Short termThe market may view the consolidation of a profitable subsidiary and the retention of experienced leadership as a positive step toward financial recovery.
📈 Long termThe merger simplifies the corporate structure and could lead to operational efficiencies, but the company still faces structural challenges including high debt and consistent quarterly losses.
⚠ Risk flags
- Regulatory risk (NCLT approval for merger)
- High Debt-to-Equity ratio (7.82)
- Continued operational losses at the parent level
Key Highlights
Approved merger of Ayurvedagram Heritage Wellness Centre (FY26 Turnover: Rs 15.47 Cr) with Kerala Ayurveda Ltd
Subsidiary Ayurvedagram reported a profit of Rs 3.16 Cr for FY26, contrasting with the parent's standalone loss of Rs 14.74 Cr
Grant of 64,875 ESOPs under the 2023 Plan at a deeply discounted exercise price of Rs 10 per share
Subsidiary Net Worth of Rs 16.23 Cr to be integrated, significantly impacting the parent's standalone Net Worth of Rs 36.15 Cr (as per filing)
Re-appointment of Mr. Ramesh Vangal, former Chairman of Seagram Asia Pacific, as Non-Executive Director
👀 What to Watch
Investors should monitor the NCLT approval timeline for the merger and observe if the consolidation of the profitable wellness unit helps stabilize the parent company's overall negative OPM (-13.5%).
Kerala Ayurveda to Merge Profitable Subsidiary Ayurvedagram; Grants 64,875 ESOPs
Kerala Ayurveda Ltd has approved the merger of its wholly-owned subsidiary, Ayurvedagram Heritage Wellness Centre, into itself to consolidate operations and reduce administrative costs. For FY26, the subsidiary was profitable with a PAT of ‹3.16 Cr on a turnover of ‹15.47 Cr, while the parent company reported a loss of ‹14.74 Cr. The board also approved Q1 FY27 results and granted 64,875 ESOPs at an exercise price of ‹10. The company remains highly leveraged with a debt-to-equity ratio of 7.82.
Confidence: HIGH
What changedThe company has initiated the formal merger of its profitable wellness subsidiary and granted new employee stock options.
Why it mattersConsolidating a profitable unit into a loss-making parent helps improve the overall balance sheet health and simplifies the corporate structure, though the high debt levels remain a concern.
Subsidiary PAT (FY26): ‹3.16 CrParent PAT (FY26): ‹-14.74 CrSubsidiary Turnover vs Parent Turnover: 18.1%ESOP Exercise Price: ‹10Debt-to-Equity Ratio: 7.82
📅 Short termThe merger of a profitable subsidiary is likely to be viewed positively by the market as it improves the consolidated earnings profile.
📈 Long termConsolidation may lead to operational efficiencies, but the company needs to address its high debt and consistent losses at the standalone level to achieve sustainable growth.
⚠ Risk flags
- High debt-to-equity ratio of 7.82
- Historical loss-making trend at the parent level
- Regulatory and NCLT approval risks for the merger
Key Highlights
Ayurvedagram subsidiary reported FY26 turnover of ‹15.47 Cr and a profit of ‹3.16 Cr.
Parent company Kerala Ayurveda reported a loss of ‹14.74 Cr on a turnover of ‹85.48 Cr for FY26.
Grant of 64,875 ESOPs at an exercise price of ‹10 per share, significantly below the current market price of ‹157.3.
The merger will result in no change to the shareholding pattern as the transferor is a 100% subsidiary.
Subsidiary net worth of ‹16.23 Cr will be consolidated into the parent's ‹36.15 Cr net worth (as of March 2026).
👀 What to Watch
Investors should monitor the NCLT approval timeline for the merger and evaluate the Q1 FY27 consolidated results to see if the profitable subsidiary's performance can meaningfully offset parent-level losses.
Rs 15.47 Cr turnover subsidiary to merge with Kerala Ayurveda; 64,875 ESOPs granted
Kerala Ayurveda's board has approved the merger of its wholly-owned subsidiary, Ayurvedagram Heritage Wellness Centre, into the parent company. This is a significant consolidation as the subsidiary is profitable, reporting a PAT of Rs 3.16 Cr in FY26, whereas the parent company reported a standalone loss of Rs 14.74 Cr. The merger will also bring the subsidiary's Rs 16.23 Cr net worth onto the parent's balance sheet, which currently has a high debt-to-equity ratio of 7.82. Additionally, the board granted 64,875 ESOPs at an exercise price of Rs 10 per share and approved Q1 FY27 results.
Confidence: HIGH
What changedThe company is moving from a multi-entity structure to a consolidated one by merging its profitable wellness subsidiary into the listed parent entity.
Why it mattersThis merger is strategically important as it integrates a profit-making unit directly into the loss-making parent, potentially improving the consolidated balance sheet and simplifying administrative overheads.
Subsidiary Turnover (FY26): Rs 15.47 CrSubsidiary PAT (FY26): Rs 3.16 CrParent Standalone Loss (FY26): Rs 14.74 CrESOP Exercise Price: Rs 10Subsidiary vs Parent Net Worth: 147%
📅 Short termThe market is likely to view the consolidation of a profitable unit positively, though the immediate focus will remain on the Q1 FY27 earnings performance.
📈 Long termThe merger could lead to better capital allocation and a stronger balance sheet, though the company still faces high debt levels and historical operational challenges.
⚠ Risk flags
- High Debt-to-Equity ratio (7.82)
- Regulatory and NCLT approval risks for the merger
- Historical trend of losses at the standalone level
Key Highlights
Merger of Ayurvedagram Heritage Wellness Centre (FY26 turnover: Rs 15.47 Cr) into Kerala Ayurveda Ltd.
Subsidiary reported a profit of Rs 3.16 Cr for FY26, compared to the parent's standalone loss of Rs 14.74 Cr.
Subsidiary net worth of Rs 16.23 Cr will bolster the parent's thin net worth of Rs 11 Cr.
Grant of 64,875 ESOPs at an exercise price of Rs 10, a deep discount to the current market price of Rs 157.3.
Re-appointment of Mr. Ramesh Vangal as Non-Executive Director recommended for the upcoming AGM on September 28, 2026.
👀 What to Watch
Watch for the NCLT approval timeline for the merger and monitor if the integration of the profitable wellness center helps offset the parent company's operational losses in upcoming quarters.
